Kindai University Hospital
Osaka-Sakai 590-0197
5 studies enrolling now · 8 studies all time
What they study most
Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extra-pulmonary Neuroendocrine Carcinoma, Idiopathic Pulmonary Fibrosis, Interstitial Lung Diseases, Lung Diseases, Interstitial, Neoplasm Metastasis, Neuroendocrine Neoplasms, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Progressive Pulmonary Fibrosis, Small Cell Lung Cancer, Small Cell Lung Cancer (SCLC)
Studies at this site
- DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy — Recruiting now
- A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer — Recruiting now
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast — Recruiting now
- Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations — Recruiting now
- DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers — Recruiting now
- FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression — Starting soon
- Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) — Running, not enrolling
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) — Completed